What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
CHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...
Photo: Karen Weintraub for Endpoints News June 2, 2026 12:00 PM EDT R&D What’s next for VEGF? ASCO offered clues, but answers will have to wait Max Gelman Senior Editor CHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely … Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that